Selling Genomics Services Unit to Beckman, Clinical Data Focuses on Rx, Biomarker Programs

The approximately $17 million acquisition, announced last week, will have "no impact" on Clinical Data's focus as a pharmacogenomics company, according to CEO Drew Fromkin.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories